Therapeutic interchange of H2 antagonists: Cost savings and impact on outcomes

Hospital Pharmacy

Volumn 35, Issue 4, 2000, Pages 387-392

  Howard, Richard T ^a   Wilson, James P ^b   Smeeding, James E ^b  

^a IHS Hospital   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Histamine 2 receptor (H2) antagonist; Therapeutic interchange

Indexed keywords

CIMETIDINE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; NIZATIDINE; RANITIDINE;

CONTROLLED STUDY; COST CONTROL; DRUG CHOICE; DRUG COST; DRUG PROGRAM; HOSPITAL PHARMACY; HUMAN; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; PHARMACY AND THERAPEUTICS COMMITTEE; RETROSPECTIVE STUDY; REVIEW; STRESS ULCER; THROMBOCYTOPENIA; TREATMENT FAILURE;

EID: 0034037206     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1177/001857870003500412     Document Type: Review

References (12)

1. 2-receptor antagonists. Am J Health-Syst Pharm. 1998;55:1382-6.
2. Oh T, Franko TG. Implementing therapeutic interchange of intravenous famotidine for cimetidine and ranitidine. Am J Hosp Pharm. 1990;47:1547-51.
3. Guharoy SR, Barajas M. Clinical and financial impact of collaboration between medical staff and pharmacy in streamlining histamine-2 receptor antagonist formulary. Paper presented at 28th Annual ASHP Mid-year Clinical Meeting; December 11, 1995.
4. Cognata CL, Mathews JE, Patel RV Pharmacoeconomic analysis and therapeutic interchange of famotidine for cimetidine and ranitidine. Paper presented at 28th Annual ASHP Mid-year Clinical Meeting, December 10, 1995.
5. Markowsky SJ, Santeiro ML. Automatic therapeutic substitution: Cost savings with intravenous push famotidine. Ann Pharmacother. 1995; 29: 316.
6. 2 antagonist cost reductions from a pharmacist intervention program. Paper presented at 29th Annual ASHP Mid-year Clinical Meeting; December 10, 1996.
7. 2 receptor antagonist therapeutic interchange program. Consultant Pharmacist. 1996;11:1226-40.
8. Lipsy RJ, Fennerty B, Fagan TC. Clinical review of histamine 2 receptor antagonists. Arch Intern Med. 1990;150:745-51.
9. Berardi RR, Tankanow RM, Nostrant TT. Comparison of famotidine with cimetidine and ranitidine.Clin Pharm. 1988;7:271-84.
10. Howden CW, Tytgat GN. The tolerability and safety profile of famotidine. Clinical Therapeutics. 1996;18(1):36-54.
11. 2-Antagonists: An update. Pharmacotherapy. 1987;7(6Pt 2): 110S-115S.
12. Lamothe PH, Rao E, Serra AJ, et al. Comparative efficacy of cimetidine, famotidine, ranitidine, and mylanta in postoperative stress ulcers. Gastro. 1991;100:1515-20.